StarZero All shows Try the podcast clipper →

Mark Kaganovich

Co-Founder & CEO, Tracer Biotechnologies · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

founderexecutivescientisttracerbio.com ↗

He was the co-founder and CEO of SolveBio, a genomics data infrastructure company acquired by Precision Medicine Group in 2023. He holds a PhD in Genetics from Stanford University and currently leads Tracer Biotechnologies.

9statements → 7claims → 2claims resolved → 3.78/5average certainty → 1.89/5average debate potential →

1 supported 1 partly supported 0 contradicted 5 not checkable as stated how the 7 claims stand · each chip opens the sources

1 prediction · 6 assertions · 2 insights · every statement was checked. The prediction and assertions are the 7 claims: statements the public record can support or contradict. 2 are resolved, and 5 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Mark argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Prediction Held up
Kaganovich predicts multi-billion dollar companies will emerge around DNA variant measurement
“There will be multi-billion dollar companies that will figure out how to measure those efficiently, deliver that information to the patient, and get feedback from the patient.”
Mark Kaganovich Feb 18, 2015 ▶ 7:26 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)

How they sound: speaking style how? →

235 words/min while actually speaking · 37.7 um and uh per 1k words

No argument clarity score for Mark Kaganovich: only 1 usable question→answer exchange on raw tape (a fair score needs 8+). We do not score a sample that small. Roundtable and news formats yield far fewer direct exchanges than interviews.

Measured by listening to the audio itself: 3,128 words across 1 episode of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

Everything Mark Kaganovich said on the MAD Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Assertion Not checkable as stated
Kaganovich: Genetics companies build clinical DNA tests using unmanaged public FTPs
“Every genetics company, every hospital, they design and implement tests To figure out what disease you have, or don't have, or whether you should have a child, or what drug to take based on your DNA. They use this data that's collected by academics and deposit…”
Mark Kaganovich Feb 18, 2015 ▶ 4:53 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Assertion Not checkable as stated
Kaganovich: Most people derive no actionable information from genome sequencing
“For most people, there's no information that they glean yet from it.”
Mark Kaganovich Feb 18, 2015 ▶ 1:58 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Assertion Partly supported
Kaganovich: Human genome sequencing costs plummeted from $3 billion to $1,000
“This thing can sequence your genome for a thousand dollars, and it, 10 years ago, cost, like, three billion, and was really hard.”
Mark Kaganovich Feb 18, 2015 ▶ 3:01 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Assertion Not checkable as stated
Kaganovich: Public academic genomic databases lack quality control and version tracking
“It's great data for the first, kind of, chapter one of genetics, but the problem is that there's no quality control. You don't know what, which records are right, which records aren't relevant. There's no feedback for this worked for me, this didn't work for m…”
Mark Kaganovich Feb 18, 2015 ▶ 5:57 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Prediction Held up
Kaganovich predicts multi-billion dollar companies will emerge around DNA variant measurement
“There will be multi-billion dollar companies that will figure out how to measure those efficiently, deliver that information to the patient, and get feedback from the patient.”
Mark Kaganovich Feb 18, 2015 ▶ 7:26 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Assertion Not checkable as stated
Kaganovich: Researchers distrust public genomic databases because submission standards vary wildly
“But no one trusts other people's submissions, we found, because the standards are different.”
Mark Kaganovich Feb 18, 2015 ▶ 12:23 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Insight
Kaganovich: Genetics is undergoing a horizontalization phase similar to early microprocessors
“The way we kind of see it is that, that, that inflection point has already happened. It's somewhat akin to the microprocessor that forced a lot of horizontalization, de-aggregation of the industry. I think that's happening in genetics”
Mark Kaganovich Feb 18, 2015 ▶ 15:37 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Insight
Kaganovich: Genomics infrastructure requires a Waze-like real-time patient feedback system
“If the human genome was quote unquote mapped in 2000, I think there's kind of one still needs to make the Google Maps of that, and then one after that we would need to make the ways, ah, of the human genome, where you actually have feedback, where you know som…”
Mark Kaganovich Feb 18, 2015 ▶ 19:49 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)
Assertion Not checkable as stated
Kaganovich: 23andMe's data monetization succeeded because of proper rare variant consents
“23 and Me did an enormous deal with, from data that they had. The reason it was valuable was because they had all the proper consents for this fairly rare collection of variants and clinical data associated with it.”
Mark Kaganovich Feb 18, 2015 ▶ 17:44 Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMark Capital)

Appearances (1)

EpisodeDateSpeaking time
Mark Kaganovich, SolveBio // Data Infrastructure For Genomics // Data Driven NYC (FirstMar Feb 18, 2015 16m
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 400 conversations transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more